Mural Oncology
Lei Chen is an accomplished professional in health economics and outcomes research (HEOR) with extensive experience across multiple leading pharmaceutical companies. Currently serving as the Executive Director of HEOR at Mural Oncology, Lei has previously held key roles including Head of HEOR at ADC Therapeutics and Global HEOR Lead for an early heart failure asset at Bristol-Myers Squibb. At Novartis, Lei occupied several positions, notably as Director of Global Market Access for Melanoma and as Director of US Oncology HEOR. Early career experience includes serving as Senior Manager of US Evidence-Based Medicine at sanofi-aventis. Lei Chen holds a PhD in Pharmaceutical Economics & Policy from the University of Southern California and an MD from Beijing Medical University.
This person is not in any teams
Mural Oncology
2 followers
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)